Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Daniel R RichardsonJohn F P Bridges

Abstract

The recent expansion of treatment options in acute myeloid leukemia (AML) has necessitated a greater understanding of patient preferences for treatment benefits, about which little is known. We sought to quantify and assess heterogeneity of the preferences of AML patients for treatment outcomes. An AML-specific discrete choice experiment (DCE) was developed involving multiple stakeholders. Attributes included in the DCE were event-free survival (EFS), complete remission (CR), time in the hospital, short-term side effects, and long-term side effects. Continuously coded conditional, stratified, and latent-class logistic regressions were used to model preferences of 294 patients with AML. Most patients were white (89.4%) and in remission (95.0%). A 10% improvement in the chance of CR was the most meaningful offered benefit (P < 0.001). Patients were willing to trade up to 22 months of EFS or endure 8.7 months in the hospital or a two-step increase in long-term side effects to gain a 10% increase in chance of CR. Patients diagnosed at 60 years or older (21.6%) more strongly preferred to avoid short-term side effects (P = 0.03). Latent class analysis showed significant differences of preferences across gender and insurance status. I...Continue Reading

References

Oct 2, 2008·Risk Analysis : an Official Publication of the Society for Risk Analysis·F Reed JohnsonBruce E Sands
Apr 7, 2009·British Journal of Haematology·Keith WheatleyUNKNOWN United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia
Jan 29, 2010·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Axel C Mühlbacher, Matthias Nübling
Mar 4, 2010·Leukemia & Lymphoma·Dushyant VermaFarhad Ravandi
Jun 10, 2010·Journal of Cancer Education : the Official Journal of the American Association for Cancer Education·Rosemarie Slevin PerocchiaMary Anne Bright
Jun 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·John F P BridgesJosephine Mauskopf
Mar 1, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·John F P BridgesA Brett Hauber
Jan 23, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·F Reed JohnsonJohn F P Bridges
Dec 11, 2014·Medical Care·Eleanor M PerfettoRobert S Epstein
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Mar 30, 2016·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jorien VeldwijkG Ardine de Wit
Jun 2, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lowell E SchnipperRichard L Schilsky
Jun 22, 2016·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·A Brett HauberJohn F P Bridges
Oct 18, 2016·Blood Reviews·Nikolai A PodoltsevSteven D Gore
Jun 8, 2017·Blood·Eytan M SteinMartin S Tallman
Dec 29, 2017·Current Opinion in Hematology·Kamal Menghrajani, Martin S Tallman
Jan 4, 2018·Blood Advances·Carol MansfieldCarolina Reyes
Jan 25, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sarah T HawleySteven J Katz
Feb 8, 2018·American Journal of Hematology·Elias Jabbour, Hagop Kantarjian
Feb 27, 2018·Current Hematologic Malignancy Reports·Craig S Boddy, Shuo Ma
Jun 5, 2018·The New England Journal of Medicine·Courtney D DiNardoHagop M Kantarjian
Oct 14, 2018·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Tommi TervonenEllen Janssen
Mar 9, 2019·Journal of Oncology Practice·Sarah K AndersenMatthew C Cheung
Mar 13, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ravishankar JayadevappaAlan J Wein
Mar 31, 2019·Seminars in Hematology·Thomas W LeBlanc, Harry P Erba
Jun 13, 2019·Current Medical Research and Opinion·Norah L CrossnohereJohn F P Bridges
Jul 20, 2019·Therapeutic Advances in Hematology·Eric S Winer, Richard M Stone

❮ Previous
Next ❯

Citations

Jan 20, 2021·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Norah L CrossnohereJohn F P Bridges
Feb 18, 2021·Expert Review of Hematology·Tara L Lin, Livio Pagano
Feb 12, 2021·Current Medical Research and Opinion·Sarah JanseJohn F P Bridges

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.